Targeting BCMA in Patients with Relapsed/Refractory Multiple Myeloma in 1-3 Prior Lines of Therapy - PubMed
4 hours ago
- #relapsed/refractory multiple myeloma
- #BCMA-targeting therapies
- #early relapse setting
- The treatment landscape for multiple myeloma is rapidly evolving with novel BCMA-directed therapies.
- Recent phase 3 trials have introduced CAR T-cell therapies, bispecific antibodies, and antibody-drug conjugates for patients with 1-3 prior lines of therapy.
- Treatment selection depends on factors like age, fitness, comorbidities, treatment exposure, and access.
- Shared decision-making is crucial due to variations in trial designs, patient populations, and real-world applicability.